BioWorld: The founders of the U.K.-listed gene editing technology firm Horizon Discovery plc, Alberto Bardelli and Chris Torrance, have re-emerged in a new startup that has a therapeutic focus.
30.11.2017
Neophore to prod cancer into neoantigen expression by targeting DNA mismatch repair
More news
16.09.2025
NeoPhore's CEO Presents at Morgan Stanley 23rd Annual Global Healthcare Conference | September 2025
NeoPhore's CEO - Michael Shih - recently presented the NeoPhore story at the Morgan Stanley Global Healthcare Conference on Monday September 8th …
16.12.2024
Neophore appoints Michael Shih as Chief Executive Officer
NeoPhore appoints Michael Shih as Chief Executive Officer Highly experienced corporate development leader with a track record of international pharma …
22.05.2024
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore …